Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets

ENHANZE®Positive

AI Analysis

Summary

Halozyme announced a global collaboration and license agreement with GSK to develop subcutaneous formulations of multiple oncology targets using its ENHANZE® platform, marking the first ENHANZE agreement to include ADC targets with first clinical trial projected to initiate in 2026.

Clinical Trial Data

Outcome Details

Global collaboration and license agreement for subcutaneous formulations of multiple oncology targets including ADC targets

Importance:7/10

Sentiment:

0.70

partnershiplicensingoncologyADCsubcutaneous formulation

Related Companies

$HALO

Read the original article

Published by PR Newswire Biotech on May 7, 2026 1:00 PM

Read Original